Following a 6-month period of adding metformin 850 mg daily to CSII therapy in T1D, a reduction in insulin requirements and total/LDL-cholesterol was observed despite unchanged glycemic control (357). The gene discussed is INS; the disease is type 1 diabetes mellitus.